Zhongfu Technology (300692.SZ) plans to jointly invest with Hefei SDIC to acquire control of Junke Zhengyuan

Zhitong Finance App News, Zhongfu Technology (300692.SZ) announced that the company's wholly-owned subsidiary Zhongfu Junke Zhengyuan (Anhui) Biomedical Technology Co., Ltd. (“Zhongfu Zhengyuan”) and Junke Zhengyuan (Beijing) Pharmaceutical Research Co., Ltd. (“Junke Zhengyuan”) and related parties intend to sign the “Equity Transfer Agreement” and its supplementary agreements to acquire control of Junke Zhengyuan and its integrated CRO assets. The acquisition capital is 1 billion yuan, which is funded through a combination of its own capital, external institutional investment, and bank mergers and acquisitions.

In order to use the professional resources and investment capabilities of professional investment institutions to accelerate the acquisition process of Junke Zhengyuan, the company plans to jointly invest with Hefei State-owned Capital Venture Capital Co., Ltd. (“Hefei SDIC”) to acquire control of Junke Zhengyuan. Zhongfu Zhengyuan plans to increase the registered capital from 100 million yuan to 400 million yuan, completing the capital increase in three phases. Among them, the company or company designates eligible entities (if any) to increase the capital by a total of 104 million yuan. Funds managed by Hefei SDIC: Hefei Construction Investment Emerging Industry Equity Investment Fund Partnership (Limited Partnership) (“Emerging Industry Fund”) and other investors (if any) will increase the total capital by 196 million yuan. After the first phase of the capital increase was completed, the company held 51% of Zhongfu Zhengyuan's shares, and the Emerging Industry Fund and other investors (if any) held 49% of Zhongfu Zhengyuan's shares.

Innovative pharmaceutical devices and CXO are one of the core business directions of the company's future development strategy. Junke Zhengyuan is a leading domestic enterprise in the field of innovative drug bioanalysis. Its core business is providing clinical sample bioanalysis and testing services for pharmaceutical R&D companies. This investment is one of the company's initiatives to lay out innovative pharmaceutical devices and CXO related industries. It plans to promote the continuous implementation of the company's innovative pharmaceutical devices and CXO business by obtaining control of Junke Zhengyuan.